U.S. Transportation Stock News

If you are wondering whether Fair Isaac's share price still makes sense after a strong multi year run, you are not alone. A closer look at value is where things get interesting. The stock last closed at US$1,281.64, with returns of 91.2% over 3 years and 171.6% over 5 years. This comes even as the price has seen a 4.7% decline over 7 days, a 17.0% decline over 30 days, a 22.0% decline year to date and a 26.0% decline over 1 year. Recent coverage around Fair Isaac has focused on its role in...

Talos Energy (TALO) is back in focus after the company updated its 2025 operational guidance, pairing a higher total production forecast with lower capital expenditure ahead of its upcoming Q4 and full year 2025 results. See our latest analysis for Talos Energy. Those guidance tweaks and the upcoming Q4 and full year 2025 earnings are landing against a backdrop where the share price is US$13.14, with a 1 month share price return of 14.46% and a 1 year total shareholder return of 48.64%...

Why Nu Holdings’ expansion plans are on investors’ radar Nu Holdings (NU) has drawn investor attention after outlining a multi year push to expand and upgrade offices across Latin America and other regions, backed by conditional approval for a U.S. national bank charter. See our latest analysis for Nu Holdings. Even with the office expansion plans, F1 partnership and conditional U.S. bank charter in focus, Nu Holdings’ recent performance has cooled in the short term, with a 1 month share...

If you are wondering whether Solaris Energy Infrastructure is still fairly priced after its run, this article will walk through what the current share price might already be assuming about the business. The stock closed at US$50.67, with a 1 year return of 52.3% and a very large 3 year return, although the last 7 days and 30 days show declines of 10.5% and 5.6%, and the year to date move sits at 0.8%. Recent news around Solaris Energy Infrastructure has focused on its role in US energy...

If you are wondering whether JPMorgan Chase is still reasonably priced or starting to look stretched, you are in the right place to assess what you are actually paying for each US$ of the bank. The stock last closed at US$297.67, with a 1.6% decline over the past 7 days, flat performance over the past 30 days, an 8.5% decline year to date, but a 16.2% return over 1 year and around 125% over both 3 and 5 years. This naturally raises questions about how much value is already reflected in the...

In recent days, UP Fintech Holding Ltd saw a surge in bullish options activity, with call option volumes tripling and implied volatility rising ahead of its now-released earnings report. This unusual options positioning highlights how derivatives traders are tactically using leverage to express expectations about UP Fintech’s near‑term fundamentals and potential earnings surprises. We’ll now examine how this spike in bullish options activity ahead of earnings could influence UP Fintech’s...

XPeng stock at a glance after recent performance XPeng (NYSE:XPEV) has come under pressure recently, with the share price showing a 0.3% decline over the past day, about 2.1% over the past week, and roughly 8.8% over the past month. Over the past 3 months, XPeng has recorded a total return decline of about 18.8%, while the year-to-date move sits near a 14% decline, keeping the stock in focus for investors tracking China based EV makers. See our latest analysis for XPeng. With the share price...

The U.S. Supreme Court recently struck down Trump-era tariffs, reducing import costs for manufacturers such as MasTec, which relies on components and materials sourced from abroad. MasTec also announced it will host an Investor Day in New York City on May 12, 2026, giving investors fresh insight into its strategy, growth drivers, and financial objectives at a time when input cost pressures may be easing. Next, we’ll explore how lower tariff-related input costs could influence MasTec’s...

If you are wondering whether EVERTEC's current share price still reflects its true potential, or if the market has marked it down too far, this article is for you. With EVERTEC's share price at US$25.78 and share price returns of a 2.2% decline over 7 days, 13.5% decline over 30 days, 10.1% decline year to date, 21.4% decline over 1 year, 29.3% decline over 3 years and 28.1% decline over 5 years, many investors are asking what the stock is really worth now. Recent coverage has focused on...

Why Jackson Financial (JXN) Is On Investors’ Radar Now Jackson Financial (JXN) has drawn fresh attention after recent share price moves, with the stock down about 5% over the past week and showing mixed shorter term returns that contrast with its longer term record. See our latest analysis for Jackson Financial. That recent 1 day share price decline of about 4.9% and the 7 day and 30 day share price returns in the low single digit negatives sit against a 90 day share price return of 13.2% and...

In February 2026, Medtronic plc reported third-quarter fiscal 2026 results showing higher sales of US$9,017 million but lower net income of US$1,143 million year-on-year, reaffirmed full-year EPS guidance of US$5.62 to US$5.66, and received U.S. FDA clearance for its Stealth AXiS spine surgical system. These updates, alongside a US$381 million antitrust jury verdict against Medtronic and ongoing diabetes-business restructuring, highlight a company balancing innovation and legal, margin, and...

Barrick Mining (B) has drawn fresh attention after its 2025 name change from Barrick Gold Corporation, shifting investor focus to how its broader mix of gold, copper, silver, and energy materials supports the current valuation. See our latest analysis for Barrick Mining. The latest US$49.22 share price comes after a 25.82% 90 day share price return and an 11.66% year to date share price return, while the 1 year total shareholder return of 175.10% suggests recent momentum has been strong...

Regeneron Pharmaceuticals and Sanofi recently received U.S. FDA approval for Dupixent to treat allergic fungal rhinosinusitis (AFRS) in adults and children aged 6 and older with a history of sino-nasal surgery, following a Priority Review supported by a Phase 3 trial showing marked improvements in sinus disease and symptoms. This ninth U.S. approval for Dupixent broadens its role in type 2 inflammatory diseases and introduces the first medicine specifically approved for AFRS, potentially...

PagSeguro Digital stock moves ahead of earnings PagSeguro Digital (PAGS) recently declined 6.38%, underperforming broader market losses, as investors focus on the company’s upcoming March 4 earnings report and what it might reveal about business momentum. See our latest analysis for PagSeguro Digital. The recent 6.38% 1 day share price decline comes after a period of mixed momentum, with a 7.86% 90 day share price return and a 43.27% 1 year total shareholder return, contrasting with a much...

ICON (NasdaqGS:ICLR) is in focus after uncovering a revenue overstatement of under 2% for 2023 and 2024, delaying its Q4 and full year 2025 results and drawing a federal securities investigation. See our latest analysis for ICON. ICON’s latest revenue overstatement and the resulting regulatory scrutiny come after a sharp reset in market expectations, with a 30 day share price return of 43.94% decline and a 1 year total shareholder return of 47.45% decline, even as the recent 7 day share price...

Resideo Technologies (REZI) is drawing attention after recent trading left the shares at a last close of US$34.60, with a mixed return profile over the past year and over multi-year periods. See our latest analysis for Resideo Technologies. Recent trading has been choppy, with a 1-day share price return of 5.77% and a 7-day share price return of 3.43% pulling back some of the gains from a 90-day share price return of 8.77%. At the same time, the 1-year total shareholder return of 77.44% and...

EPR Properties (EPR) has drawn fresh attention after a sustained run in its unit price, with the REIT now sitting near US$59. That move, alongside its value score, is prompting closer scrutiny. See our latest analysis for EPR Properties. At the current share price of US$59.03, EPR Properties has posted a 30 day share price return of 8.97% and a year to date share price return of 16.29%, while its 1 year total shareholder return of 25.65% and 3 year total shareholder return of 78.25% point to...

Vulcan Materials (NYSE:VMC) has scheduled an Investor Day event for March 12, 2026. The company will webcast the event, featuring presentations from the CEO and senior management. Management plans to share its current business outlook, strategic priorities, and operational plans with investors. For you as an investor, this Investor Day is an opportunity to hear directly from Vulcan Materials' leadership about how they see the business today. The company’s share price stands at $310.79, with...

Dividend move puts Mach Natural Resources in focus Mach Natural Resources (MNR) drew the attention of income-focused investors after its board declared a fourth quarter 2025 cash distribution of $0.53 per common unit, payable on March 12, 2026. See our latest analysis for Mach Natural Resources. At a last close of $13.50, Mach Natural Resources has seen its short term momentum build, with a 30 day share price return of 18.11% and year to date share price return of 20.00%, even though the 1...

Liberty Global (LBTY.A) is back in focus after reporting full year 2025 results, with sales of US$4,878.5 million and a net loss of US$7,138.1 million, reversing from net income a year earlier. See our latest analysis for Liberty Global. Investors appear to be reassessing Liberty Global after the earnings release, with a 1-day share price return of 2.47% and a 7-day share price return of 18.00% on the way to a 1-year total shareholder return of 13.02%. This suggests recent momentum has picked...

If you are wondering whether GitLab's current share price reflects its real worth, you are not alone. This article is all about unpacking what the numbers suggest about value. GitLab shares last closed at US$24.03, after returns of an 18.7% decline over 7 days, a 33.9% decline over 30 days, a 33.6% decline year to date, and a 61.4% decline over the past year, with a 45.0% decline over 3 years. Recent coverage around GitLab has focused on its position within the software sector and how...

In recent days, AbbVie announced a US$380 million plan to build two AI-enabled active pharmaceutical ingredient facilities in North Chicago and secured US FDA approval for an all-oral, fixed-duration VENCLEXTA plus acalabrutinib regimen for previously untreated chronic lymphocytic leukemia patients. Together, these moves highlight AbbVie’s push to deepen its oncology footprint while scaling future neuroscience and obesity drug production within its US manufacturing base. We’ll now examine...

Virewirx previously announced a US$1.9 million Phase II contract to develop an advanced 5G system, naming Globalstar as a key technology collaborator, while Globalstar also scheduled its fourth-quarter 2025 earnings release for February 27 before the market opened. This pairing of a specialized 5G collaboration with ongoing satellite and network investments highlights how Globalstar is pushing deeper into complex hybrid connectivity solutions. We’ll now examine how Globalstar’s role in...

If you are wondering whether BioCryst Pharmaceuticals is attractively priced at its recent share price of US$7.58, you are not alone. This article will focus on what that number might really represent for long term investors. The stock has recently shown mixed momentum, with a 12.1% move over the past 7 days and 11.6% over 30 days, while the 1 year return sits at a decline of 8.6% and the 5 year return at a decline of 36.7%. These moves come against a backdrop of ongoing market attention on...